Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

JDOC vs SCHLX overlap: 65% of top holdings shared

Bottom line

How much do JDOC and SCHLX overlap?

65% of their top holdings overlap by weight. 16 securities appear in both funds' top 25, making up 59.6% of JDOC's assets and 59.4% of SCHLX's. They share a meaningful core but differ in the rest of the portfolio.

Updated Nov 22, 2026

Overlap at a glance

JDOCSCHLX
Weight overlap (top 25)65%
Shared holdings16
Weight in shared holdings59.6%59.4%
Total positions6165
Expense ratio0.65%1.06%
Holdings as ofJul 31, 2026May 31, 2026

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Holdings JDOC and SCHLX have in common

Holding% of JDOC% of SCHLXOverlap
AbbVie, Inc.7.85%4.90%4.90%
Eli Lilly & Co.7.76%13.85%7.76%
UnitedHealth Group, Inc.5.85%5.73%5.73%
Merck & Co., Inc.4.82%4.85%4.82%
Johnson & Johnson4.82%6.19%4.82%
AstraZeneca plc3.76%3.80%3.76%
Thermo Fisher Scientific, Inc.3.73%3.46%3.46%
Bristol-Myers Squibb Co.3.57%1.50%1.50%
Abbott Laboratories3.11%2.39%2.39%
Roche Holding AG2.82%1.24%1.24%
Stryker Corp.2.23%2.61%2.23%
Danaher Corp.2.16%2.13%2.13%
Cencora, Inc.2.07%1.26%1.26%
Intuitive Surgical, Inc.1.93%2.69%1.93%
Regeneron Pharmaceuticals, Inc.1.60%1.43%1.43%
Cardinal Health, Inc.1.51%1.34%1.34%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in JDOC

  1. CVS Health Corp. — 2.83%
  2. Novo Nordisk A/S — 2.61%
  3. GSK plc — 2.47%
  4. Argenx SE — 2.06%
  5. Edwards Lifesciences Corp. — 1.73%
  6. IQVIA Holdings, Inc. — 1.71%
  7. Teva Pharmaceutical Industries Ltd. — 1.60%
  8. Novartis AG — 1.60%
  9. Biogen, Inc. — 1.56%

Only in SCHLX

  1. Novartis AG — 2.90%
  2. Amgen Inc — 2.88%
  3. Gilead Sciences Inc — 2.78%
  4. Vertex Pharmaceuticals Inc — 2.45%
  5. Boston Scientific Corp — 2.10%
  6. McKesson Corp — 2.05%
  7. Novo Nordisk A/S — 1.73%
  8. Medtronic PLC — 1.54%
  9. Pfizer Inc — 1.17%

Asset mix

Asset typeJDOCSCHLX
Stocks99.2%99.6%
Cash & short-term funds—0.5%

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Country mix

CountryJDOCSCHLX
US75.2%85.7%
GB6.2%3.8%
CH4.4%5.2%
DK4.0%1.7%
JP2.5%—
NL2.4%1.0%
DE1.9%—
IL1.6%—

Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)

Check another pair

FAQ

How much do JDOC and SCHLX overlap?
About 65% by weight. 16 securities appear in both funds' top 25 holdings; they make up 59.6% of JDOC's assets and 59.4% of SCHLX's. They share a meaningful core but differ in the rest of the portfolio.
What stocks do JDOC and SCHLX have in common?
The largest shared holdings are Eli Lilly & Co., UnitedHealth Group, Inc., AbbVie, Inc., Merck & Co., Inc., Johnson & Johnson.
Should I own both JDOC and SCHLX?
They overlap in part. Owning both concentrates you in the shared names; check that the combined weight in those stocks is what you intend.
Which holds more stocks, JDOC or SCHLX?
SCHLX is broader, with 65 positions versus 61 for JDOC. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.